HC Wainwright initiated coverage on shares of Entasis Therapeutics (NASDAQ:ETTX) in a research note issued to investors on Monday, 24/7 WallStreet reports. The brokerage issued a buy rating and a $18.00 target price on the stock.
A number of other analysts also recently issued reports on ETTX. Zacks Investment Research cut Entasis Therapeutics from a buy rating to a hold rating in a report on Monday, May 20th. ValuEngine upgraded Entasis Therapeutics from a hold rating to a buy rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $16.75.
NASDAQ ETTX opened at $8.34 on Monday. Entasis Therapeutics has a 12 month low of $3.97 and a 12 month high of $13.70. The company has a 50-day moving average of $6.72 and a 200-day moving average of $6.47. The company has a debt-to-equity ratio of 0.03, a current ratio of 9.11 and a quick ratio of 9.11. The company has a market cap of $108.36 million and a P/E ratio of -0.68.
An institutional investor recently bought a new position in Entasis Therapeutics stock. BlackRock Inc. purchased a new stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,755 shares of the company’s stock, valued at approximately $56,000. BlackRock Inc. owned 0.11% of Entasis Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 65.08% of the stock is currently owned by institutional investors.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Article: Why is the price-sales ratio important?
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.